

## Qiagen expands digital PCR portfolio with new lentivirus solutions

01 May 2025 | News

**To help accelerate the development of safe and effective biotherapeutics**



Qiagen has announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalised form of cancer immunotherapy.

This expanded offering supports standardised, high-precision quality control (QC) workflows and strengthens the position of QIAGEN as a trusted partner for quality control, supporting biotech and biopharma companies, Contract Development and Manufacturing Organisations (CDMO) and therapy developers in CGT manufacturing.

The **QIAcuity RCL Quant Kit** detects replication-competent lentivirus (RCL), a key safety concern in lentiviral vector production. The kit uses clear step-by-step protocols to find even small amounts of RCL, helping therapy developers meet regulations and keep treatments safe.

The new **QIAcuity CGT dPCR assays**, including eight different wet-lab verified lentiviral targets, are designed for viral vector genome titration (measuring the amount of therapeutic virus particles) and vector copy number (VCN) determination (counting how many copies of a gene are inserted into each cell).

The new **CGT Lentivirus Lysis Kit and protocol**, combined with QIAcuity CGT dPCR assays, enables vector genome titer quantification with fewer hands-on steps, enhanced accuracy and repeatability.